Skip to main content
Top
Published in: Digestive Diseases and Sciences 1/2021

01-01-2021 | Clostridioides Difficile | EDITORIAL

FMT for Severe C. difficile Infection: If at First You Do No Harm, the Second Time’s a Charm

Author: Ari Grinspan

Published in: Digestive Diseases and Sciences | Issue 1/2021

Login to get access

Excerpt

Over the past 10 years, there has been a substantial increase in the use of fecal microbiota transplantation (FMT) to treat recurrent Clostridioides difficile infection (CDI) after failed antibiotic therapy. Most medical societies across the world have incorporated FMT into their guidelines in recognition of the effectiveness of this treatment for recurrent CDI. The global cure rate of CDI after FMT is reported to be between 80 and 90%. The clinical quandary is what to do with the 10–20% of patients that fail a first FMT. While there have been several studies exploring the risk factors for FMT failure such as severe/fulminant infection, inpatient status at time of FMT, and multiple CDI-related hospitalizations, there are no clear guidelines on how to proceed after a patient fails an initial FMT [1, 2]. …
Literature
1.
go back to reference Fischer M, Kao D, Mehta SR, et al. Predictors of early failure after fecal microbiota transplantation for the therapy of Clostridium difficile infection: a multicenter study. Am J Gastroenterol. 2016;111:1024–1031.CrossRef Fischer M, Kao D, Mehta SR, et al. Predictors of early failure after fecal microbiota transplantation for the therapy of Clostridium difficile infection: a multicenter study. Am J Gastroenterol. 2016;111:1024–1031.CrossRef
2.
go back to reference Patron RL, Hartmann CA, Allen S, et al. Vancomycin taper and risk of failure of fecal microbiota transplantation in patients with recurrent Clostridium difficile infection. Clin Infect Dis. 2017;65:1214–1217.CrossRef Patron RL, Hartmann CA, Allen S, et al. Vancomycin taper and risk of failure of fecal microbiota transplantation in patients with recurrent Clostridium difficile infection. Clin Infect Dis. 2017;65:1214–1217.CrossRef
3.
go back to reference Agrawal M, Aroniadis OC, Brandt LJ, et al. The long-term efficacy and safety of fecal microbiota transplant for recurrent, severe, and complicated Clostridium difficile infection in 146 elderly individuals. J Clin Gastroenterol. 2016;50:403–407.PubMed Agrawal M, Aroniadis OC, Brandt LJ, et al. The long-term efficacy and safety of fecal microbiota transplant for recurrent, severe, and complicated Clostridium difficile infection in 146 elderly individuals. J Clin Gastroenterol. 2016;50:403–407.PubMed
5.
go back to reference Allegretti JR, Allegretti AS, Phelps E, et al. Classifying fecal microbiota transplantation failure: an observational study examining timing and characteristics of fecal microbiota transplantation failures. Clin Gastroenterol Hepatol. 2018;16:1832–1833.CrossRef Allegretti JR, Allegretti AS, Phelps E, et al. Classifying fecal microbiota transplantation failure: an observational study examining timing and characteristics of fecal microbiota transplantation failures. Clin Gastroenterol Hepatol. 2018;16:1832–1833.CrossRef
6.
go back to reference Fischer M, Sipe BW, Rogers NA, et al. Faecal microbiota transplantation plus selected use of vancomycin for severe-complicated Clostridium difficile infection: description of a protocol with high success rate. Aliment Pharmacol Ther. 2015;42:470–476.CrossRef Fischer M, Sipe BW, Rogers NA, et al. Faecal microbiota transplantation plus selected use of vancomycin for severe-complicated Clostridium difficile infection: description of a protocol with high success rate. Aliment Pharmacol Ther. 2015;42:470–476.CrossRef
8.
go back to reference Shogbesan O, Poudel DR, Victor S, et al. A systematic review of the efficacy and safety of fecal microbiota transplant for Clostridium difficile infection in immunocompromised patients. Can J Gastroenterol Hepatol. 2018;2018:1394379.CrossRef Shogbesan O, Poudel DR, Victor S, et al. A systematic review of the efficacy and safety of fecal microbiota transplant for Clostridium difficile infection in immunocompromised patients. Can J Gastroenterol Hepatol. 2018;2018:1394379.CrossRef
9.
10.
go back to reference Luo Y, Lucas AL, Grinspan AM. Fecal transplants by colonoscopy and capsules are cost-effective strategies for treating recurrent Clostridioides difficile infection. Dig Dis Sci. 2020;65:1125–1133.CrossRef Luo Y, Lucas AL, Grinspan AM. Fecal transplants by colonoscopy and capsules are cost-effective strategies for treating recurrent Clostridioides difficile infection. Dig Dis Sci. 2020;65:1125–1133.CrossRef
Metadata
Title
FMT for Severe C. difficile Infection: If at First You Do No Harm, the Second Time’s a Charm
Author
Ari Grinspan
Publication date
01-01-2021
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 1/2021
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-020-06309-z

Other articles of this Issue 1/2021

Digestive Diseases and Sciences 1/2021 Go to the issue